Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide Combined With Fulvestrant in HR+/HER2- Advanced Breast Cancer
NCT05047848Unknown
- Sponsor
- Liaoning Medical Center
- Start
- Aug 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tucidinostat in breast cancer, sponsored by Liaoning Medical Center. Primary endpoint: Overall Response Rate at 26 months. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05047848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05047848.